One Test for All


Linearis Labs and Linearis Ventures | Our Mission

Through identification of multi-omics disease signatures, we accelerate the innovation cycle in prevention, treatment monitoring and AI drug discovery companies.


Linearis Labs | About our work

Linearis Labs is expanding omics testing and discovery capabilities.

We work with leaders in both AI and metabolomics to generate quantitative and actionable AI-friendly data as part of their AI pipelines. Some recent work involves omics signatures for COVID-19 and cancer.

Linearis Labs operates from our recently acquired laboratory.

What we do | Our disease signature discovery platform

Linearis Labs couples high throughput technology and mass spectrometry to provide metabolomics analysis of blood plasma or serum for diseases including cancer, diabetes and anti-microbial resistance which have significant metabolomics components.

Using an AI pipeline, disease signatures are discovered and can provide actionable insights for of several types of metabolomic diseases, improve effectiveness of therapeutic interventions, and prevent the emergence of resistance and side effects of treatments.

What we do | Biobank analysis services

Linearis Labs offers metabolomics profiling services. Services include both targeted and untargeted LC-MS measurements. High throughput procedures are also available to process thousands of samples using laser diode thermal desorption mass spectrometry. The analyses are carried out in a certified environment and are of clinical grade.

The data is made available in an AI-friendly format for machine learning-based analysis. Linearis Labs can also perform data analysis with state-of-the-art machine learning algorithms.

As metabolomics is closer to the phenotype of interest, it provides a great advantage for biobanks to acquire metabolomics data (e.g. UK Biobank). Moreover, there is an expectation that multi-omics analyses will be required for better interpretation of the diseases under analysis.

Linearis Ventures | What we do

Linearis Ventures, the responsible AI health fund, provides access to capital and disease signatures in Cancer, AMR and Diabetes to facilitate diagnosis, monitoring treatment and improve drug discovery for our partners.